JP2007515386A5 - - Google Patents

Download PDF

Info

Publication number
JP2007515386A5
JP2007515386A5 JP2006526959A JP2006526959A JP2007515386A5 JP 2007515386 A5 JP2007515386 A5 JP 2007515386A5 JP 2006526959 A JP2006526959 A JP 2006526959A JP 2006526959 A JP2006526959 A JP 2006526959A JP 2007515386 A5 JP2007515386 A5 JP 2007515386A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
antigen
derived
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515386A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/029844 external-priority patent/WO2005027835A2/en
Publication of JP2007515386A publication Critical patent/JP2007515386A/ja
Publication of JP2007515386A5 publication Critical patent/JP2007515386A5/ja
Pending legal-status Critical Current

Links

JP2006526959A 2003-09-18 2004-09-14 Ｈｉｖ感染個体の治療用免疫化 Pending JP2007515386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50452203P 2003-09-18 2003-09-18
PCT/US2004/029844 WO2005027835A2 (en) 2003-09-18 2004-09-14 Therapeutic immunization of hiv-infected individuals

Publications (2)

Publication Number Publication Date
JP2007515386A JP2007515386A (ja) 2007-06-14
JP2007515386A5 true JP2007515386A5 (enExample) 2007-08-02

Family

ID=34375517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526959A Pending JP2007515386A (ja) 2003-09-18 2004-09-14 Ｈｉｖ感染個体の治療用免疫化

Country Status (7)

Country Link
US (1) US20060216272A1 (enExample)
EP (1) EP1663114A2 (enExample)
JP (1) JP2007515386A (enExample)
CN (1) CN101076247A (enExample)
AU (1) AU2004273832A1 (enExample)
CA (1) CA2535645A1 (enExample)
WO (1) WO2005027835A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077859A2 (en) * 2002-03-13 2003-09-25 Merck & Co., Inc. Method of inducing an enhanced immune response against hiv
ES2361000T3 (es) * 2004-04-28 2011-06-13 The Trustees Of The University Of Pennsylvania Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado.
EA012037B1 (ru) 2004-11-16 2009-06-30 Круселл Холланд Б.В. Поливалентные вакцины, содержащие рекомбинантные вирусные векторы

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
WO2001002607A1 (en) * 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US20040063653A1 (en) * 2000-12-21 2004-04-01 Shiver John W. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
AU2001233063A1 (en) * 2000-01-31 2001-08-07 Aaron Diamond Aids Research Center Vaccination of hiv infected persons following highly active antiretroviral therapy
SG152045A1 (en) * 2001-01-26 2009-05-29 Immune Response Corp Inc Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment

Similar Documents

Publication Publication Date Title
LaBranche et al. HIV fusion and its inhibition
Laguette et al. Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins
Asselah et al. Second‐wave IFN‐based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir
JP2012509340A5 (enExample)
JP2003535043A5 (enExample)
Soltani et al. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection
JP2010539901A5 (enExample)
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
De Goede et al. Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection
JP2013507107A5 (enExample)
Dletrich et al. The epidemiology of HIV in India
JP2007515386A5 (enExample)
Salemi et al. The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy
JP2007505923A5 (enExample)
Dios et al. Adverse effects of antiretroviral therapy: focus on orofacial effects
JP2002508338A5 (enExample)
JP2008500963A5 (enExample)
Ueno et al. Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide
JP2010530356A5 (enExample)
Iversen et al. Preferential detection of HIV subtype C′ over subtype A in cervical cells from a dually infected woman
Tan et al. Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection
Artenstein et al. Transmission of HIV-1 subtype E in the United States
Puoti et al. Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV
Otuechere Repurposing of chloroquine and its derivative, hydroxychloroquine for COVID-19: implications for people living with HIV in Africa
WO2000045844A1 (en) Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv